240 related articles for article (PubMed ID: 22571348)
1. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
[TBL] [Abstract][Full Text] [Related]
2. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
3. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
5. Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month.
Schouten van der Velden AP; Punt CJ; Van Krieken JH; Derleyn VA; Ruers TJ
Eur J Surg Oncol; 2008 Mar; 34(3):353-5. PubMed ID: 17207961
[TBL] [Abstract][Full Text] [Related]
6. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
[TBL] [Abstract][Full Text] [Related]
7. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
[TBL] [Abstract][Full Text] [Related]
8. [Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].
Gómez-Ramírez J; Martín-Pérez E; Amat CG; Sanz IG; Bermejo E; Rodríguez A; Larrañaga E
Cir Esp; 2010 Dec; 88(6):404-12. PubMed ID: 20971458
[TBL] [Abstract][Full Text] [Related]
9. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
11. Sinusoidal obstruction syndrome (SOS): A light and electron microscopy study in human liver.
Vreuls CP; Driessen A; Olde Damink SW; Koek GH; Duimel H; van den Broek MA; Dejong CH; Braet F; Wisse E
Micron; 2016 May; 84():17-22. PubMed ID: 26914502
[TBL] [Abstract][Full Text] [Related]
12. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
Morris-Stiff G; Tan YM; Vauthey JN
Eur J Surg Oncol; 2008 Jun; 34(6):609-14. PubMed ID: 17764887
[TBL] [Abstract][Full Text] [Related]
13. Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer.
Vreuls CP; Olde Damink SW; Koek GH; Winstanley A; Wisse E; Cloots RH; van den Broek MA; Dejong CH; Bosman FT; Driessen A
Br J Cancer; 2013 Feb; 108(3):676-80. PubMed ID: 23287989
[TBL] [Abstract][Full Text] [Related]
14. Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome.
Schiffer E; Frossard JL; Rubbia-Brandt L; Mentha G; Pastor CM
J Surg Oncol; 2009 Jun; 99(7):439-46. PubMed ID: 19353590
[TBL] [Abstract][Full Text] [Related]
15. Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.
Martins J; Alexandrino H; Oliveira R; Cipriano MA; Falcão D; Ferreira L; Martins R; Serôdio M; Martins M; Tralhão JG; Prado e Castro L; Castro E Sousa F
Eur J Surg Oncol; 2016 May; 42(5):713-21. PubMed ID: 26972374
[TBL] [Abstract][Full Text] [Related]
16. A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction.
Narita M; Hatano E; Ikai I; Miyagawa-Hayashino A; Yanagida A; Nagata H; Asechi H; Taura K; Uemoto S
Ann Surg; 2009 May; 249(5):806-13. PubMed ID: 19387321
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
18. Sinusoidal obstruction syndrome in the animal model: influence on liver surgery.
Jafari A; Wehner S; Kalff JC; Manekeller S
Langenbecks Arch Surg; 2017 Feb; 402(1):115-122. PubMed ID: 27585678
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
20. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
